



16538

RECEIVED
SEP 05 2002
TECH CENTER 1600/2900

Docket No. 199509150PCT
IN RE APPLICATION OF: Francesco PARENTI, et al.
SERIAL NO: 09/744,247
FILED: January 30, 2001
FOR: INJECTABLE FORMULATIONS CONTAINING RAMOPLANIN

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Transmitted herewith is an **amendment and request for reconsideration w/ marked-up copy** in the above-identified application.

- ☐ No additional fee is required
☐ Small entity status of this application under 37 C.F.R. §1.9 and §1.27 is claimed.
☒ Additional documents filed herewith: **Substitute Abstract**

The Fee has been calculated as shown below:

CLAIMS	CLAIMS REMAINING		HIGHEST NUMBER PREVIOUSLY PAID	NO. EXTRA CLAIMS	RATE	CALCULATIONS
TOTAL	42	MINUS	35	7	x \$18 ? =	\$126.00
INDEPENDENT	1	MINUS	3	0	x \$84 =	\$0.00
		<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS			+ \$280 =	\$0.00
		TOTAL OF ABOVE CALCULATIONS				\$126.00
		<input type="checkbox"/> Reduction by 50% for filing by Small Entity				\$0.00
		<input type="checkbox"/> Recordation of Assignment			+ \$40 =	\$0.00
		TOTAL				\$126.00

- ☒ A check in the amount of **\$126.00** is attached.
- ☒ Please charge any additional Fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.
- ☒ If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 C.F.R. §1.136, and any additional fees required under 37 C.F.R. §1.136 for any necessary extension of time may be charged to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.



22850

Customer Number 22850
Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 10/01)

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

James J. Kelly

Registration No. 41,504



Handwritten signature and date: 9/13/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

FRANCESCO PARENTI ET AL.

: GROUP ART UNIT: 1653

SERIAL NO.: 09/744,247

FILED: JANUARY 30, 2001

: EXAMINER: LUKTON, D.

FOR: INJECTABLE FORMULATIONS
CONTAINING RAMOPLANIN

AMENDMENT AND REQUEST FOR RECONSIDERATION

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

RECEIVED

SEP 05 2002

TECH CENTER 1600/2900

SIR:

In response to the Office Action dated May 30, 2002, Applicants respectfully request reconsideration in light of the following remarks.

IN THE ABSTRACT OF THE DISCLOSURE

At page 31, after the last line and beginning on the next page, please insert the Abstract of the Disclosure attached hereto.

IN THE SPECIFICATION

Please replace the paragraph on page 1, lines 18-26 with the following:

B1 Ramoplanin factors A₁, A₂ and A₃ have been described in EP-B-318680, the aglycones of any of the above factors have been described in US 5,491,128 while the tetrahydrogenated derivatives of any of the above factors have been described in US 5,108,988. A method for selectively increasing the ratio of single major components A₂ and

65/03/2002 10:41:11 00000040 09744247

126.00 OP

01 FC:103